Birmingham, AL Clinical Trials Report — July 2026

Birmingham participants should act now if they match a study nearing its enrollment deadline: 41 recruiting trials are expected to close within the next 90 days, including 9 that accept healthy volunteers. The closing studies cover atopic dermatitis, acute stress reaction, apnea of prematurity, hip and knee arthritis, traumatic or surgical amputation, wound care, adolescent behavior, astrocytoma, and alveolar mucosa.

Birmingham remains one of Alabama’s largest clinical research centers, with 945 recruiting trials across 337 facilities. However, only 14 new studies opened in July, down from 21 in June and 19 in May. That makes early contact especially useful for people interested in a closing study, because enrollment may end before the projected date if the target number of participants is reached.

Closing opportunities for patients and healthy volunteers

Atopic dermatitis is the most common condition among Birmingham’s closing-soon studies, with 3 trials. Other affected areas include:

• Acute stress reaction (1 trial)
• Apnea of prematurity (1 trial)
• Alveolar mucosa (1 trial)
• Traumatic or surgical amputation (1 trial)
• Amputation wound care (1 trial)
• Adolescent behavior (1 trial)
• Hip arthritis (1 trial)
• Knee arthritis (1 trial)
• Astrocytoma (1 trial)

Nine of the 41 closing studies accept healthy volunteers. Across Birmingham overall, 121 trials are currently recruiting healthy participants. Eligibility can still depend on age, medications, medical history, laboratory results, and the amount of time required for visits, so healthy volunteers should review screening requirements promptly rather than assume that general good health is sufficient.

New Phase 2 and Phase 3 studies bring broad opportunities

July’s new trials include 6 behavioral studies, 4 drug trials, 3 studies classified as other, one biological study, one device study, and one dietary-supplement study. The conditions represented include cancer, advanced biliary tract cancer, chronic lower back pain, cystic fibrosis, ACL problems, allergic reaction, arthroscopic surgery, exercise training, and behavior change.

• NCT07720271, Novo Nordisk’s Phase 3 AMAZE 9 study, is testing once-daily zenagamtide tablets for people with excess body weight. The study plans to enroll 950 participants and compares zenagamtide with placebo.
• NCT07731256 is a Phase 2 study sponsored by Washington University School of Medicine testing semaglutide for chronic low back pain. It plans to enroll 250 participants and examines whether treatment may reduce pain through weight loss and other effects.
• NCT07723534 is a Phase 2 study of zolbetuximab combined with either CAPOX or mFOLFOX6 for advanced or metastatic biliary tract cancers with Claudin 18.2 overexpression. The study plans to enroll 32 participants, with chemotherapy selection based on investigator judgment and participant preference.
• NCT07696338, the REACT trial sponsored by Nicole Hamblett, includes randomized studies of hypertonic saline and dornase alfa therapies for people with cystic fibrosis. The planned enrollment is 405 participants.
• NCT07682324 is a Phase 2 University of Alabama at Birmingham study of daily encapsulated green tea extract for cancer survivors with established cancer-associated neuropathic pain. It plans to enroll 20 participants.

University of Alabama at Birmingham sponsors 9 of the new studies, making it the leading sponsor in July. Other listed sponsors include Novo Nordisk A/S, Washington University School of Medicine, Aquestive Therapeutics, Midhun Malla, and Nicole Hamblett. Academic and other non-industry organizations account for 12 new studies, compared with 2 industry-sponsored openings.

UAB is the main access point for local research

The University of Alabama at Birmingham is by far the largest clinical research hub in the city. Its main listing has 291 recruiting trials, while affiliated UAB and cancer-center listings add substantial additional activity. Cancer patients may find particularly strong opportunities through UAB Cancer Center, while UAB’s broader academic programs also cover surgery, behavioral health, chronic pain, cystic fibrosis, metabolic conditions, and other specialties.

• University of Alabama at Birmingham (291 trials)
• University of Alabama at Birmingham Cancer Center (60 trials)
• Children’s Hospital of Alabama (41 trials)
• University of Alabama Birmingham (26 trials)
• Research Site (26 trials)
• University of Alabama (25 trials)
• The University of Alabama at Birmingham (24 trials)
• UAB (12 trials)
• Children’s of Alabama (12 trials)
• Birmingham VA Medical Center (10 trials)
• University of Alabama Hospital (10 trials)
• Grandview Medical Center (6 trials)

Several listings represent related UAB, hospital, cancer-center, or children’s facilities, so people should confirm the exact location and study team when contacting a trial. Four of July’s new studies include children, and 11 include older adults. No new study is limited to female or male participants.

Other Alabama cities to consider

People willing to travel beyond Birmingham can also look for recruiting studies in Dothan (2), Auburn, Daphne, Gadsden, Homewood, Montgomery, Anniston, and Tuscaloosa, with 1 listed trial in each of those cities. Availability and eligibility may differ substantially by location, so participants should ask whether a study has an active local site rather than relying only on the city listing.

With July’s new-study total below each of the preceding five months—13 in February, 20 in March, 21 in April, 19 in May, and 21 in June—Birmingham’s existing trial base remains the key source of opportunities. Patients, caregivers, and healthy volunteers who find a suitable study should contact the UAB-area site soon, while the next months may bring additional openings in cancer, metabolic health, pain, pediatrics, and behavioral research.